KMT2A, lysine methyltransferase 2A, 4297

N. diseases: 535; N. variants: 65
Disease: Neoplasm, Residual ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE This study provides a comprehensive analysis of the MLL recombinome in acute leukemia and demonstrates that the establishment of patient-specific chromosomal fusion sites allows the design of specific PCR primers for minimal residual disease analyses for all patients. 28701730 2018
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE RESULTS We divided 41 patients into 2 groups according to the variation of MRD (minimal residual disease) level of the MLL gene. 27561414 2016
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 AlteredExpression phenotype BEFREE A high level of MRD was associated with high WBC counts, increased age, BCR-ABL1 fusion gene, MLL rearrangements and adverse karyotypes. 27212157 2016
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE MLL rearrangements are important for therapy stratification, assessment of minimal residual disease and for targeted therapies. 25510485 2015
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 AlteredExpression phenotype BEFREE Intriguingly, clonally expanded non-leukemic cells expressing MLL-ELL during consolidation therapy were found to be eradicated after allo-HSCT during the monitoring of minimal residual disease in one patient; this indicates that allo-HSCT is efficacious for eliminating pre-leukemic cells resistant to chemotherapy. 25758097 2015
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 AlteredExpression phenotype BEFREE The expression of the MLL gene had a higher specificity and sensitivity than WT1 or MRD monitored by FCM for predicting the relapse of the patients with MLL + AL. 24631740 2014
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE A higher specific hazard of relapse was independently associated with postinduction MRD level ≥10(-4) and unfavorable genetic characteristics (ie, MLL gene rearrangement or focal IKZF1 gene deletion in BCP-ALL and no NOTCH1/FBXW7 mutation and/or N/K-RAS mutation and/or PTEN gene alteration in T-cell ALL). 24740809 2014
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE This MLL-MLLT3 RT-qPCR assay could be useful in MRD monitoring of a group of patients with AML who often lack reliable MRD markers. 23772754 2013
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE We also showed that BCR-ABL and MLL rearrangements, the prednisone response, and MRD were independent prognostic factors. 22911440 2012
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Most sensitive methodology to detect MRD is molecular polymerase chain reaction (PCR) but its applicability is restricted to AML with leukemia-specific molecular targets (e.g.AML1-ETO, CBFB-MYH11, MLL, FLT-3). 22196957 2012
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 AlteredExpression phenotype BEFREE Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene. 21953510 2011
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Monitoring of the minimal residual disease load with quantitative real-time PCR can be performed for NPM1 and MLL-PTD-mutated cases. 20805748 2010
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE From a clinical practice standpoint, this case illustrates the importance of detection of MLL rearrangement due to its prognostic implication and the effectiveness of flow cytometry immunophenotyping in diagnosing MPAL and monitoring minimal residual disease. 20299091 2010
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE Furthermore, the genomic fusion site in MLL rearrangements represent a unique and reliable molecular marker that allows the tracing of minimal residual disease (MRD) in these patients before, during, and after therapy. 19277576 2009
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 AlteredExpression phenotype BEFREE The identification and characterization of MLL rearrangement at the genomic DNA level may be useful for MRD quantification. 19380030 2009
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 AlteredExpression phenotype BEFREE The precise characterization of the MLL-AF9 transcript is important to carry out the minimal residual disease analysis during the follow-up of the patients. 18000862 2008
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Molecular analysis of the 11q23/MLL rearrangement was used to evaluate minimal residual disease, which became undetectable in repetitive FISH analyses. 18367831 2008
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE MRD was evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) using probes derived from fusion chimeric genes (BCR/ABL and MLL/AF4) (n=22) or rearrangements of the T-cell receptor or immunoglobulin genes (n=21). 17488684 2007
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Furthermore, the determined patient-specific fusion sequences are useful for minimal residual disease monitoring of MLL associated acute leukemias. 15626757 2005
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 AlteredExpression phenotype BEFREE Levels of minimal residual disease (MRD) at the end of induction appeared to be high in infants with ALL compared with older children, and although the number of infant cases studied was small, there were no differences in MRD levels after induction therapy in infant ALL with or without MLL gene rearrangements (P = 0.41) and quantitative MRD assessment at the early time points may not be predictive of outcome. 16197448 2005
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype LHGDN A partial tandem duplication within the MLL-gene (MLL-PTD) can be found in 8% of all patients with karyotypically normal acute myeloid leukemia (AML), a group in which polymerase chain reaction-(PCR) based minimal residual disease analysis has not, so far, been possible. 15996925 2005
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE In conclusion, immunophenotyping may be a suitable approach to investigating MRD status in AML patients with PTD of the MLL gene. 12529663 2003
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Thus, genomic MLL-AF4 fusion genes are a good alternative target for the analysis of MRD in patients with t(4;11) leukaemias. 11972513 2002
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Reverse transcriptase-polymerase chain reaction (RT-PCR) used to detect MLL/LTG4 chimeric mRNA showed no minimal residual disease (MRD) in the graft or bone marrow at the transplantation. 11699212 2001
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE Minimal residual disease in acute monocytic leukemia patient with trisomy 11 and partial tandem duplication of MLL. 9209466 1997